Actimed plans trials to treat muscle wasting syndrome in cancer patients
The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.
Frewitt WP
Atrial fibrillation market set to decline at a CAGR of 1.3% between 2022 and 2032
Virpax plans three trials based on platform drug delivery systems in 2024
FDA approves Skyline Therapeutics’ IND for macular degeneration trial
Olema Oncology traces pivotal trial pathway after business challenges
Eloxx repackages ELX-02 data in cystic fibrosis as it eyes pivotal trial
AstraZeneca ends Phase IV Andexxa trial after positive results
FDA accepts GSK’s sBLA for Jemperli to treat endometrial cancer
